Market Place
Sourcing Support
All News #Library
Others
Auron Doses First Patient in Phase 1 Trial of AUTX-703
29 May 2025 //
GLOBENEWSWIRE
Auron Therapeutics to Present Poster at 2025 AACR Meeting
26 Mar 2025 //
GLOBENEWSWIRE
Auron Therapeutics Appoints Glenn Goddard As CFO
19 Mar 2025 //
GLOBENEWSWIRE
Auron Receives FDA Clearance for AUTX-703 & Series B Financing
04 Feb 2025 //
GLOBENEWSWIRE
Auron Presents Preclinical Data for AUTX-703 in AML at ASH 2024
09 Dec 2024 //
GLOBENEWSWIRE
Auron Presents Preclinical Data on AUTX-703 at ASH 2024 Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
19 Aug 2024 //
GLOBENEWSWIRE
Auron: AURIGIN„ Platform Preclinical Data At AI Symposia
01 May 2024 //
GLOBENEWSWIRE
Auron Reveals Preclinical Data on AURIGIN Platform at AACR
10 Apr 2024 //
GLOBENEWSWIRE
Auron Reveals AURIGIN Platform Data at AACR Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
06 Mar 2024 //
GLOBENEWSWIRE
Auron Selects First Development Candidate for Targeted Cancer Treatments
08 Feb 2024 //
GLOBENEWSWIRE
Auron Strengthens Board of Directors with Victoria Richon & Christopher Guiffre
10 Aug 2023 //
GLOBENEWSWIRE
Auron Establishes Scientific Advisory Board to Support AI-Powered Platform
01 Aug 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.